Autres langues BioStem Techn. OTC Markets

Actions

BSEM

US0906842002

Marché Fermé - OTC Markets Autres places de cotation 21:56:30 03/05/2024			Varia. 5j.	Varia. 1 janv.
8,22 ^USD	-8,57%		-9,72%	+40,27%

2023

NovaBay commercialisera l'allogreffe de tissu amniotique de BioStem

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioStem Technologies Granted Prioritized Examination for Wound Healing Patent	14:02
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts	30/04
BioStem Technologies to Present at the 2024 Planet MicroCap Showcase	25/04
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange	24/04
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference	02/04
BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase	01/04
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024	21/03
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market	26/02
Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies	30/01
BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role	11/01
BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors	19/12
Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions	14/12
BioStem Technologies Bolsters Leadership with Appointment of Thomas Dugan to Board of Directors	13/12
BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results	13/11
BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services	08/11
BioStem Technologies Closes Oversubscribed $2M Private Placement	03/11
BioStem Technologies to Highlight Core Advanced Wound Care Portfolio at SAWC Fall 2023 Conference	18/10/23
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova Allograft	15/09/23
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft	12/09/23
NovaBay to Commercialize BioStem's Amniotic Tissue Allograft	11/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioStem Techn. OTC Markets

Actions

BSEM

US0906842002

Autres langues

Filtres